Chung YS, et al. - In non-high-grade serous carcinoma (HGSC) patients with advanced-stage ovarian cancer, researchers evaluated outcomes following the receipt of neoadjuvant chemotherapy (NAC). Based on histological subtypes, evaluation of demographics, surgical outcomes, and survival rates was carried out in this retrospective cohort study. Among 154 included patients, mucinous adenocarcinoma was present in 20 (13.0%), endometrioid adenocarcinoma in 31 (20.1%), clear cell carcinoma in 28 (18.2%), low-grade serous carcinoma in 29 (18.8%), and carcinosarcoma in 12 (7.8%). In patients with mucinous and clear cell carcinoma undergoing NAC, poor survival outcomes were observed. For this disease subset different treatment strategies are needed for better survival outcomes.